Cargando…
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard o...
Autores principales: | Tinker, Anna V., Altman, Alon D., Bernardini, Marcus Q., Ghatage, Prafull, Gien, Lilian T., Provencher, Diane, Salvador, Shannon, Doucette, Sarah, Oza, Amit M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221681/ https://www.ncbi.nlm.nih.gov/pubmed/35735457 http://dx.doi.org/10.3390/curroncol29060348 |
Ejemplares similares
-
Paraneoplastic myositis secondary to poorly differentiated serous carcinoma of ovarian/tubal origin
por: Raizman, Zachary, et al.
Publicado: (2017) -
Low-Grade Serous Carcinoma of the Ovary: The Current Status
por: Babaier, Abdulaziz, et al.
Publicado: (2022) -
Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications
por: Rambau, Peter, et al.
Publicado: (2017) -
A rapidly evolving landscape: immune checkpoint inhibitors in
pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023) -
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)